Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism

Por Sanchez Spitman, A. B., Moes, D. J. A. R., Gelderblom, H., Dezentje, V. O., Swen, J.J., Guchelaar, H. J.
Publicado no Eur J Clin Pharmacol (2017)

A comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group

Por Bank, P.C.D., Caudle, K.E., Swen, J.J., Gammal, R.S., Whirl-Carrillo, M., Klein, T.E., Relling, M.V., Guchelaar, H.-J.
Publicado no Clin Pharmacol Ther (2017)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

Por Birdwell, KA, Decker, B, Barbarino, JM, Peterson, JF, Stein, CM, Sadee, W, Wang, D, Vinks, AA, He, Y, Swen, JJ, Leeder, JS, van Schaik, RHN, Thummel, KE, Klein, TE, Caudle, KE, MacPhee, IAM
Publicado no Clin Pharmacol Ther (2015)

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer

Por Diekstra, MH, Fritsch, A, Kanefendt, F, Swen, JJ, Moes, DJAR, Sörgel, F, Kinzig, M, Stelzer, C, Schindele, D, Gauler, T, Hauser, S, Houtsma, D, Roessler, M, Moritz, B, Mross, K, Bergmann, L, Oosterwijk, E, Kiemeney, LA, Guchelaar, HJ, Jaehde, U
Publicado no CPT Pharmacometrics Syst Pharmacol (2017)